Study of Efficacy and Safety of the Plasmapheresis Method With Albumin Compensation Compared With the Plasmapheresis Method Without Albumin Compensation for Aging Biomarkers Correction in Men and Women Aged 40 to 55 Years Old

Diabetes Clinical Trial

Official title:

Multicenter, Open, Prospective, Randomized Trial of Efficacy and Safety of the Plasmapheresis Method With Albumin Compensation Compared With the Plasmapheresis Method Without Albumin Compensation for Aging Biomarkers Correction in Men and Women Aged 40 to 55 Years Old

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04897113
• Other study ID #: RU-RB-01-01-21 of 08.02.2021
• Status: Recruiting
• Phase: N/A
• Start date: May 12, 2021
• Est. completion date: December 30, 2022

Study information

• Verified date: May 2021
• Source: National Medical Research Center for Rehabilitation and Balneology
• Contact: Ilmira Gilmutdinova
• Phone: +79686861979
• Email: gilm.ilmira[@]mail.ru
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Reaching active aging makes it important to implement new methods affecting the biological age of a person. Biochemical parameters of a blood test are aging biomarkers that are ones of the most accessible for testing. We know that, with age, there is increase in levels of LDL, triglycerides, homocysteine and other biomarkers relating the body state. Methods of extracorporeal hemocorrection showed good results in this area. For instance, the use of plasmapheresis is very effective during prophylaxis, treatment and rehabilitation after various diseases/injuries. The main effects of plasmapheresis are related to removal of endo- and exotoxins, including products of lipid peroxidation, and to draining effect as a result of a heavy flow of interstitial fluid containing products of pathometabolism into the blood stream within concentration gradient (by "dynamic equilibrium" in concentration of different substances in intracellular, interstitial and intravascular compartments). These effects are also related to release of receptors, their sensitization to their own neurohumoral regulation mechanisms, to insulin, in particular (as consequences, lower glucose tolerance, lower substrate glycation).

Description:

Reaching active aging makes it important to implement new methods affecting the biological age of a person. Biochemical parameters of a blood test are aging biomarkers that are ones of the most accessible for testing. We know that, with age, there is increase in levels of LDL, triglycerides, homocysteine and other biomarkers relating the body state. One of the initial approaches of anti-ageing therapy is detoxification, reocorrection and immunocorrection. Methods of extracorporeal hemocorrection showed good results in this area. For instance, the use of plasmapheresis is very effective during prophylaxis, treatment and rehabilitation after various diseases/injuries. The main effects of plasmapheresis are related to removal of endo- and exotoxins, including products of lipid peroxidation, and to draining effect as a result of a heavy flow of interstitial fluid containing products of pathometabolism into the blood stream within concentration gradient (by "dynamic equilibrium" in concentration of different substances in intracellular, interstitial and intravascular compartments). These effects are also related to release of receptors, their sensitization to their own neurohumoral regulation mechanisms, to insulin, in particular (as consequences, lower glucose tolerance, lower substrate glycation). Thus, at this stage, experts assess effectiveness and organize data of existing prevention methods for premature aging and correction of aging biomarkers, as well as develop comprehensive programs for drug-free and pharmacological intervention. Introduction of the body detoxification method based on extracorporeal hemocorrection (developed in FGBU Russian Scientific Center for Medical Rehabilitation and Balneology of Ministry of Health of Russian Federation) may extend the range of effective and safe methods within such programs, as well as lower patients' biological age and, thus, lower risks of developing age-related diseases, decrease number of disability cases, which can contribute to life prolonging and improvement of its quality.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: December 30, 2022
• Est. primary completion date: October 30, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years to 55 Years

Eligibility

Inclusion Criteria:

• Signed informed consent form.
• Men and women aged 40-55.
• Body mass index <30 kg / m2.
• Level increase of one or several aging markers.
• Understanding of requirements for study participants, written consent to participate in the study (including volunteer's consent for his/her health information related to the study to be used and passed on) and to perform procedures outlined in study protocol.
• Negative pregnancy test for women of childbearing potential.

Non-inclusion Criteria:

• Refusal to participate in the study.
• Any health conditions that, according to investigators, might prevent volunteers from participating in the study.
• Mental disorders, past medical history included.
• 10 + alcohol units per week (one alcohol unit equals 0,5 l of beer, 200 ml of wine or 50 ml of hard liquors) or any records of alcohol addiction.
• Drug addiction, chemical abuse.
• Pregnancy or breastfeeding.
• Past medical history of severe allergic reactions.
• General contraindications to plasmapheresis procedures.
• Any other health conditions or reasons that, according to investigators, might increase risks for participants or reduce the likelihood of results needed to meet the study goals.

Exclusion Criteria:

• Voluntary refusal to participate in the study.
• Investigator doctor's decision on participant's exclusion for this participant's own benefit.
• Participant refuses to cooperate with investigator or is undisciplined.
• In case participant misses one or several study procedures or follow-up visits.
• Development of severe adverse reactions or severe diseases/conditions unrelated to the study, requiring withdrawal from therapy.
• Positive pregnancy test.

Related Conditions & MeSH terms

• Cardiovascular Diseases
• Diabetes
• Gout
• Hyper-LDL-cholesterolemia
• Hyperbilirubinemia
• Hypercholesterolemia
• Hypereosinophilic Syndrome
• Hyperlipoproteinemia Type II
• Job Syndrome
• Nervous System Diseases
• Neuromuscular Diseases
• Syndrome
• Urologic Diseases

Intervention

Procedure:
• plasma exchange with albumin
plasma exchange with albumin, two per week, 110% of the circulating plasma volume
• plasma exchange without albumin
plasma exchange without albumin, two per week, 110% of the circulating plasma volume

Locations

Country	Name	City	State
Russian Federation	Federal State Budgetary Institution "National Medical Center for Rehabilitation and Balneology" of the Ministry of Health of Russia	Moscow
Russian Federation	Orenburg regional clinical blood transfusion station	Orenburg

Sponsors (4)

Lead Sponsor	Collaborator
National Medical Research Center for Rehabilitation and Balneology	DNKOM LLC, Pirogov Russian National Research Medical University, The Orenburg Regional Clinical Hospital

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dynamics summary for improvement of aging biomarkers' values assessed by a patient's biochemical blood count	Dynamics summary for improvement of aging biomarkers' values assessed by a patient's biochemical blood count at visit 6, compared with initial values (visit 0).	1 month
Secondary	Dynamics summary for improvement of aging biomarkers' values assessed by a patient's biochemical blood count	Dynamics summary for aging biomarkers' values assessed by a patient's biochemical blood count at visit 5, compared with initial values (visit 0).	17 (+/- 2) days
Secondary	Dynamics summary for aging biomarkers' values assessed by a patient's complete blood count	Dynamics summary for aging biomarkers' values assessed by a patient's complete blood count at visits 5 and 6, compared with initial values (visit 0).	1 month
Secondary	Dynamics summary for aging biomarkers' values assessed by a patient's blood serological test	Dynamics summary for aging biomarkers' values assessed by a patient's blood serological test at visits 5 and 6, compared with initial values (visit 0).	1 month
Secondary	Dynamics summary for aging biomarkers' values assessed by a patient's coagulation test	Dynamics summary for aging biomarkers' values assessed by a patient's coagulation test at visits 5 and 6, compared with initial values (visit 0).	1 month
Secondary	Dynamics of results according to the method of "phenotypic age"	Dynamics of results according to the method of "phenotypic age" assessment with the use of values of complete and biochemical blood counts at visits 5 and 6, compared with initial values (visit 0).; An assessment of the "phenotypic age" will be carried out (Morgan E. et al., 2018). For counting, 10 markers are used: albumin, creatinine, glucose, C-reactive protein, percentage of lymphocytes, average cell volume, distribution width of erythrocytes, alkaline phosphatase, leukocyte count, chronological age.	1 month
Secondary	Dynamics of results according to the method of biological age	Dynamics of results according to the method of biological age assessment with the use of values of complete and biochemical blood counts at visits 5 and 6, compared with initial values (visit 0). The biological age will be assessed by the method of Putin E., Mamoshina P. et al., 2016. The following markers are used for calculation by this method: albumin, glucose, urea, cholesterol, total protein, sodium, creatinine, hemoglobin, total bilirubin, triglycerides , HDL cholesterol, LDL cholesterol (Friedewald), calcium, potassium, hematocrit, MCHC, MCV, platelets, erythrocytes (erythrocytes), weight, height.; An online system available at http://www.aging.ai will be used to estimate biological age.	1 month
Secondary	Dynamic pattern according to ECG results	Dynamic pattern according to ECG results in 12 leads at visits 5 and 6, compared with initial values (visit 0).	1 month
Secondary	Dynamic pattern according to results of vascular ultrasonography	Dynamic pattern according to results of vascular ultrasonography at visits 5 and 6, compared with initial values (visit 0).	1 month
Secondary	SF-36 scale	Change of scores according to every scale out of all 8 scales from the SF-36 questionnaire at visits 5, 6 and 7, compared with initial values (visit 0).	1 month
Secondary	HAM questionnaire	Dynamics of subjective assessment of a patient's current psycho emotional state (HAM questionnaire) at visits 5, 6 and 7, compared with initial values (visit 0). The Hamilton Rating Scale for Depression (HRSD), also called the Hamilton Depression Rating Scale (HDRS), abbreviated HAM-D, is a multiple-item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery.	1 month
Secondary	scales of the "Health-Promoting Lifestyle Profile"	Change of scores according to every scale out of 6 scales of the "Health-Promoting Lifestyle Profile" questionnaire at visits 5, 6 and 7, compared with initial values (visit 0).	1 month